Source: https://www.federalregister.gov/documents/2019/11/18/2019-24921/pan-american-laboratories-llc-et-al-proposal-to-withdraw-approval-of-four-new-drug-applications
Timestamp: 2020-05-28 05:42:33
Document Index: 265466474

Matched Legal Cases: ['§\u2009314', '§\u2009314', 'art 314', '§\u2009314', 'art 12', '§\u2009314']

Federal Register :: Pan American Laboratories, LLC, et al.; Proposal To Withdraw Approval of Four New Drug Applications; Opportunity for a Hearing
The NDA holders may submit a request for a hearing by December 18, 2019. Submit all data, information, and analyses upon which the request for a hearing relies January 17, 2020. Submit electronic or written comments by January 17, 2020.
Docket No. FDA-2019-N-4992
FDA-2019-N-4992
https://www.federalregister.gov/d/2019-24921 https://www.federalregister.gov/d/2019-24921
Start Preamble Start Printed Page 63661
The request for a hearing may be submitted by the NDA holders by either of the following methods:
Because your request for a hearing will be made public, you are solely responsible for ensuring that your request does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. The request for a hearing must include the Docket No. FDA-2019-N-4992 for “Pan American Laboratories, LLC, et al.; Proposal To Withdraw Approval of Four New Drug Applications; Opportunity for a Hearing.” The request for a hearing will be placed in the docket and publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
The NDA holders may submit all data and analyses upon which the request for a hearing relies in the same manner as the request for a hearing except as follows:
Instructions: All submissions received must include the Docket No. FDA-2019-N-4992 for “Pan American Laboratories, LLC, et al.; Proposal To Withdraw Approval of Four New Drug Applications; Opportunity for a Hearing.” Received comments, those filed in a timely manner (see DATE ), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked Start Printed Page 63662as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/​fdsys/​pkg/​FR-2015-09-18/​pdf/​2015-23389.pdf.
Kimberly S. Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137.
The holders of approved applications to market new drugs for human use are required to submit annual reports to FDA concerning each of their approved applications in accordance with § 314.81 (21 CFR 314.81). The NDA holders listed in table 1 have failed to submit the required annual reports and have not responded to the Agency's request for submission of the reports.
NDA 014217 MAOLATE (chlorphenesin carbamate) Tablet, 400 milligrams (mg) Pan American Laboratories, LLC, 4099 Highway 190, Covington, LA 70433.
NDA 018663 CHYMODIACTIN (chymopapain) for Injection, 4,000 Units/vial and 10,000 Units/vial Chart Medical, Inc., c/o Renascent Medical, Inc., 9600 Great Hills Trail, Suite 150 West, Austin, TX 78759.
NDA 020530 IONTOCAINE (epinephrine and lidocaine hydrochloride (HCl)) Topical Solution, 0.01 mg/milliliter; 2% Iomed, Inc., 2441 South 3850 West, Suite A, Salt Lake City, UT 84120-9941.
NDA 021504 LIDOSITE TOPICAL SYSTEM: LidoSite Patch (lidocaine HCl and epinephrine topical iontophoretic patch) 10%/0.1% and LidoSite Controller Vyteris, Inc., 13-01 Pollitt Dr., Fair Lawn, NJ 07410.
Therefore, notice is given to the NDA holders listed in table 1 and to all other interested persons that the Director of CDER proposes to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(e)), withdrawing approval of the applications and all amendments and supplements thereto on the grounds that the NDA holders have failed to submit reports required under § 314.81.
In accordance with section 505 of the FD&C Act and 21 CFR part 314, the NDA holders are hereby provided an opportunity for a hearing to show why the approval of the applications listed previously should not be withdrawn and an opportunity to raise, for administrative determination, all issues relating to the legal status of the drug products covered by these applications.
An NDA holder who decides to seek a hearing must file the following: (1) A written notice of participation and request for a hearing (see DATES and ADDRESSES) and (2) the data, information, and analyses relied on to demonstrate that there is a genuine and substantial issue of fact that requires a hearing (see DATES and ADDRESSES). Any other interested person may also submit comments on this notice. The procedures and requirements governing this notice of opportunity for a hearing, notice of participation and request for a hearing, information and analyses to justify a hearing, other comments, and a grant or denial of a hearing are contained in § 314.200 (21 CFR 314.200) and in 21 CFR part 12.
The failure of an NDA holder to file a timely written notice of participation and request for a hearing, as required by § 314.200, constitutes an election by that NDA holder not to avail itself of the opportunity for a hearing concerning CDER's proposal to withdraw approval of the applications and constitutes a waiver of any contentions concerning the legal status of the drug products. FDA will then withdraw approval of the applications, and the drug products may not thereafter be lawfully introduced or delivered for introduction into interstate commerce. Any new drug product introduced or delivered for introduction into interstate commerce without an approved application is subject to regulatory action at any time.
[FR Doc. 2019-24921 Filed 11-15-19; 8:45 am]